New CEO commentary — “Redefining aging with HoloMonitor”

June 4, 2018
Language flag

In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television. By studying primitive bacteria researchers at Queensland University of Technology in Australia have been able to develop a new drug that has the potential to dramatically slow the aging process. The newscast reports that by using the company’s cell analyzer HoloMonitor the researchers were able to see how old and damaged cells became young.

Latest News

Peter Egelberg CEO PHI

Founder and board member subscribes for shares in the ongoing rights issue

Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
AndersMansson-web

PHI at Aktieportföljen Live, BioStock and Financial Stockholm

The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ) 8 January 2025

The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.
See All News